Thailand: Researchers plan to begin human trials of potential COVID-19 vaccine

While scientists around globe are struggling to develop a COVID-19 vaccine, researchers in Thailand are planning to begin human trials in vember of a potential vaccine for dely virus. According to an international media outlet, Thai researchers are preparing 10,000 doses so that a vaccine could be rey for use by late next year. Kiat Ruxrungtham, director of Bangkok's Chulalongkorn University vaccine development program, said that results of trials on primates have been ‘favourable’ and w next step is to manufacture doses for human trails. 

While 10 candidates are being trailed in humans globally, Kiat said that trials will t accept volunteers until facility receives approval from Thai Food and Drug ministration and an ethics committee. Furr, director of vaccine development program said that Thai company BioNet-Asia is preparing its facilities for large-scale manufacturing if trials prove successful. 

RE: Bill Gates Says COVID-19 Vaccine Should Reach Those Who Need, Warns Of 'delier Pandemic'

Thailand’s first facility is expected to complete production of doses in October and n send products to second facility, which should finish by vember. While speaking at a news conference, Kiat said that officials h earlier planned to complete manufacturing by June, however, ‘it was t easy to plan everything’. He also ded that originally  earliest target to start human trails was September but t eugh vaccine could have been rey by n. 

Kiat said, “If everything goes according to plan, vaccine will be rey for Thailand in third or fourth quarter next year”. 

RE: Tuberculosis Vaccine May Reduce Coronavirus-related Deaths: Study

China starts phase III trials 

Meanwhile, China is leing race with an experimental vaccine by Sivac Biotech Ltd. Earlier this month, Chinese company anunced that it was entering phase III clinical trials sponsored by Instituto Butantan, Brazil, to test  efficacy of its experimental COVID-19 vaccine. As one of three pharmaceutical companies to reach  late sts of trials, Sivac said it will recruit over 9,000 healthcare professionals to speed up process to invent potential cure for COVID-19. 

In collaboration with Butantan, a leing Brazilian producer of immubiological products and vaccines, Sivac has been given approval to run widescale trials by  Brazilian National Regulatory ncy, Anvisa. human trials aim to be pivotal for licensure of product as Anvisa alrey reviewed  manufacturing and clinical information of  coronavirus vaccines. According to reports, Anvisa conducted  highest standards review of vaccines as it is a member of International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (“ICH”). 

(Im: AP)

RE: UK Will t Take Part In EU Vaccine Program; To Maintain Brexit Ideology

RE: US Bets On Small, Untested Company To Deliver COVID Vaccine